Phase 1 first-in-human study of anti-ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results

被引：0

作者：

Gutierrez, Martin

Spreafico, Anna

Wang, Ding

Golan, Talia

Renouf, Daniel

Voskoboynik, Mark

Chatterjee, Manash Shankar

Kapadia, Kishan J.

Liu, Qi

Kovvali, Gopala

Suttner, Leah

Pang, Ling

Chen, Mei

Tolcher, Anthony W.

机构：

[1] Hackensack Univ Med Ctr, Hackensack, NJ USA

[2] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Merck Co Inc, Kenilworth, NJ USA

[4] Henry Ford Hosp, Detroit, MI USA

[5] Tel Aviv Univ, Sheba Med Ctr, Ramat Gan, Israel

[6] BC Cancer, Vancouver, BC, Canada

[7] Univ British Columbia, Vancouver, BC, Canada

[8] Monash Univ, Cent Clin Sch, Alfred Hlth, Melbourne, Vic, Australia

[9] Merck Co Inc, Kenilworth, NJ USA

[10] South Texas Accelerated Res Therapeut, San Antonio, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2505

引用

页数：1

共 50 条

[21] A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors. [J].

McKean, Meredith ;

Hutson, Thomas E. ;

Piha-Paul, Sarina A. ;

Micaily, Ida ;

Liao, Mingxiang ;

Humphreys, Robin ;

Brock, Graham ;

Sahr, Natasha ;

Amber, Vian ;

Spira, Alexander I. .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[22] PHASE 1 STUDY OF AN ANTI-CD27 AGONIST AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS [J].

Shapira-Frommer, Ronnie ;

van Dongen, Marloes G. J. ;

Dobrenkov, Konstantin ;

Chartash, Elliot ;

Liu, Fang ;

Li, Claire ;

Wnek, Richard ;

Patel, Manish .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 :A2-A2

[23] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors [J].

Harvey, R. Donald ;

Falchook, Gerald Steven ;

Naqash, Abdul Rafeh ;

Kim, Joseph W. ;

Dowlati, Afshin ;

Le Bruchec, Yvan ;

Coudert, Isabelle ;

Ervin-Haynes, Annette L. ;

Sommerhalder, David .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

[24] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors [J].

Mathiot, Laurent ;

Combarel, David ;

Cagnat, Justin ;

Delahousse, Julia ;

Ouali, Kaissa ;

Marabelle, Aurelien ;

Loriot, Yohann ;

Ponce, Santiago ;

Champiat, Stephane ;

Broutin, Sophie ;

Danlos, Francois-Xavier .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)

[25] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors [J].

Joerger, Markus ;

Calvo, Emiliano ;

Laubli, Heinz ;

Lopez, Juanita ;

Alonso, Guzman ;

de la Fuente, Elena Corral ;

Hess, Dagmar ;

Konig, David ;

Perez, Vicky Sanchez ;

Bucher, Christoph ;

Jethwa, Sangeeta ;

Garralda, Elena .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)

[26] A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors. [J].

Matulonis, Ursula A. ;

Janku, Filip ;

Moser, Justin C. ;

Fu, Siqing ;

Wages, David S. ;

Wheeler, Catherine A. ;

Mori, Mikinaga ;

Shimoyama, Susumu ;

Yamada, Naoki ;

Subach, Ruth Ann ;

Cheung, Kin ;

Madden, Timothy ;

Maier, Gary ;

Johansen, Mary ;

Falchook, Gerald Steven .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

[27] Phase 1 study of anti-immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482+pembrolizumab (pembro) in patients with recurrent inoperable glioblastoma (GBM) [J].

Kim, Tae Min ;

Kim, Sang-We ;

Gutierrez, Martin ;

Di Giacomo, Anna Maria ;

Voskoboynik, Mark ;

Myer, Nicole ;

Edmondson, Mackenzie ;

Liu, Qi ;

Chen, Mei ;

Victoria, Ivan .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[28] A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01 [J].

Kichenadasse, G. ;

Lombard, J. ;

Khattak, M. A. A. ;

Lundy, J. ;

Tazbirkova, A. ;

Zhou, Q. ;

Li, Y. ;

Kudva, A. ;

Cui, H. ;

Hoe, E. ;

Lynch, K. P. ;

Chisamore, M. ;

Wu, Y-L. .

ANNALS OF ONCOLOGY, 2024, 35 :S679-S679

[29] Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors [J].

Wahlroos, Sara ;

Teng, Christina ;

Tran, Ben ;

Voskoboynik, Mark ;

Gan, Hui Kong ;

Spencer, Andrew ;

Kudva, Anupa ;

Song, Ming ;

Lynch, Kevin ;

Yu, Zhinuan ;

Desai, Jayesh ;

Lemech, Charlotte Rose ;

Lifehouse, Chris O'Brien .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[30] A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors [J].

Gutierrez, M. ;

Garralda, E. ;

Calvo, E. ;

van Dongen, M. ;

Eskens, F. A. ;

Finlay, M. ;

Menas, F. Z. ;

Zhu, C. ;

Wu, M. ;

Guillemin-Paveau, H. ;

Abbadessa, G. ;

Perez, R. ;

Yildirim, O. ;

Naing, A. .

ANNALS OF ONCOLOGY, 2023, 34 :S646-S647

← 1 2 3 4 5 →